Patents by Inventor Takuya Tamatani

Takuya Tamatani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8389690
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: February 9, 2011
    Date of Patent: March 5, 2013
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Publication number: 20120003231
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Application
    Filed: February 9, 2011
    Publication date: January 5, 2012
    Applicant: JAPAN TOBACCO INC.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7932358
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: April 26, 2011
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7662781
    Abstract: Satisfactory effects have not always been attained by immunotherapy having been tried, and reliance upon direct attack on cells by anticancer agents, radiation, etc has been inevitable. The present invention intends to provide a therapeutic method that ensures less side effects but higher efficacy than in conventional therapeutic methods through enhancing of immune strength inherently had by living organism. Thus, the present invention relates to an immunopotentiating agent comprising MIP-1? or its functional derivative as an active ingredient.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: February 16, 2010
    Assignee: ECI, Inc.
    Inventors: Shiro Kanegasaki, Takuya Tamatani
  • Patent number: 7541438
    Abstract: A human monoclonal antibody useful for the treatment of various diseases caused by human connective tissue growth factor (CTGF) and preventing the onset of the above diseases; medicinal uses thereof; and various monoclonal antibodies having various characteristics against various mammalian CTGFs useful for detecting and assaying CTGFs present in body fluids of mammals suffering from various diseases.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: June 2, 2009
    Assignee: Amgen, Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka, Shinji Sakamoto, Masaharu Takigawa
  • Publication number: 20090054318
    Abstract: Satisfactory effects have not always been attained by immunotherapy having been tried, and reliance upon direct attack on cells by anticancer agents, radiation, etc has been inevitable. The present invention intends to provide a therapeutic method that ensures less side effects but higher efficacy than in conventional therapeutic methods through enhancing of immune strength inherently had by living organism. Thus, the present invention relates to an immunopotentiating agent comprising MIP-1? or its functional derivative as an active ingredient.
    Type: Application
    Filed: December 20, 2005
    Publication date: February 26, 2009
    Inventors: Shiro Kanegasaki, Takuya Tamatani
  • Publication number: 20080248031
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Application
    Filed: November 12, 2007
    Publication date: October 9, 2008
    Applicant: JAPAN TOBACCO INC.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7294473
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: November 13, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7279560
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: October 9, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7259147
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: March 5, 2004
    Date of Patent: August 21, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7247612
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 25, 2003
    Date of Patent: July 24, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7226909
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: June 5, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7217792
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: May 15, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7196175
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: November 7, 2003
    Date of Patent: March 27, 2007
    Assignee: Japan Tobacco Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Publication number: 20060223133
    Abstract: A human monoclonal antibody useful for the treatment of various diseases caused by human connective tissue growth factor (CTGF) and preventing the onset of the above diseases; medicinal uses thereof; and various monoclonal antibodies having various characteristics against various mammalian CTGFs useful for detecting and assaying CTGFs present in body fluids of mammals suffering from various diseases.
    Type: Application
    Filed: January 4, 2006
    Publication date: October 5, 2006
    Inventors: Takuya Tamatani, Katsunari Tezuka, Shinji Sakamoto, Masaharu Takigawa
  • Patent number: 7112655
    Abstract: A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are a polypeptide of the cell surface molecule; a polypeptide fragment thereof; a fusion polypeptide comprising the fragment; a pharmaceutical composition comprising any one of the above; and methods of using the compositions.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: September 26, 2006
    Assignee: Japan Tobacco, Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7045615
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Grant
    Filed: March 26, 2002
    Date of Patent: May 16, 2006
    Assignee: Japan Tobacco, Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Patent number: 7030225
    Abstract: A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and/or experimental purpose.
    Type: Grant
    Filed: August 26, 1999
    Date of Patent: April 18, 2006
    Assignee: Japan Tobacco, Inc.
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Publication number: 20040229788
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Application
    Filed: November 25, 2003
    Publication date: November 18, 2004
    Applicant: Japan Tobacco Inc., a Japanese corporation
    Inventors: Takuya Tamatani, Katsunari Tezuka
  • Publication number: 20040151720
    Abstract: Novel cell surface molecules recognized by monoclonal antibodies against a cell surface molecule of lymphocytic cells that play an important role in autoimmune diseases and allergic diseases have been isolated, identified, and analyzed for their functions. The cell surface molecules are expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes, and induce cell adhesion. Antibodies against the cell surface molecules significantly ameliorate pathological conditions of autoimmune diseases and allergic diseases.
    Type: Application
    Filed: March 5, 2004
    Publication date: August 5, 2004
    Applicant: Japan Tobacco Inc., a Japanese corporation
    Inventors: Takuya Tamatani, Katsunari Tezuka